Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Intrathecal Administration of Double Checkpoint Inhibition in Combination with Pemetrexed in Patients with Leptomeningeal Metastasis: a Monocentric Phase I/II

Next Previous
Trial Profile

Intrathecal Administration of Double Checkpoint Inhibition in Combination with Pemetrexed in Patients with Leptomeningeal Metastasis: a Monocentric Phase I/II

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Sep 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 21 Jul 2026 Planned End Date changed from 1 Jul 2026 to 1 Sep 2027.
  • 21 Jul 2026 Planned primary completion date changed from 1 Jun 2026 to 1 Dec 2026.
  • 21 Jul 2026 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top